; and (2) by adding at the end the following: (2) Additional information Beginning with fiscal year 2018, the report under this subsection shall include the progress of the Office of Generic Drugs in achieving the goals, and future plans for meeting the goals, including— (A) the number of original abbreviated new drug applications filed per fiscal year; (B) the number of amendments to abbreviated new drug applications filed per fiscal year; and (C) the number of actions taken delineated by the type of action, including final approvals, tentative approvals, complete response letters, and the number of refuse to receive letters issued by the Food and Drug Administration per fiscal year. (3) Real time reporting (A) In general Beginning with fiscal year 2018, the Secretary shall, every 30 calendar days, post the data described in subparagraph (B) on the Internet website of the Food and Drug Administration and remove from such website duplicative data from the annual report under this subsection. (B) Data The following data is required to be posted in accordance with subparagraph (A): (i) The number and titles of draft and final guidance issued by the Office of Generic Drugs and the justification for the issuance and finalization of such guidance. (ii) The number and titles of public meetings held by the Office of Generic Drugs each fiscal year. . (d) B s UFA Section 744I(a) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–53(a) ) is amended— (1) by striking Beginning with and inserting the following: (1) General requirements Beginning with ; and (2) by adding at the end the following: (2) Additional information Beginning with fiscal year 2018, the report under this subsection shall include the progress of the Center for Biologics Evaluation and Research in achieving the goals, and future plans for meeting the goals, including— (A) information on all previous cohorts for which the Secretary has not given a complete response on all biosimilar biological product applications and supplements in the cohort